Virginia Cannabis Control Authority; draft regulations governing cannabis, report.
SB1054 directs the Virginia Cannabis Control Authority to draft a comprehensive set of regulations for an adult-use marijuana market in Virginia. The bill covers indoor cultivation, processing, manufacturing, testing, packaging, labeling, distribution, sale, and delivery of cannabis to adults age 21 or older. It also requires the Authority to include application and license fees, transaction limits, and to model the rules as closely as practicable on Virginia’s existing medical cannabis regulations.
The bill further requires the Authority to report draft regulations to the General Assembly by November 15, 2025. That report must also identify when the Authority could realistically implement and enforce the regulations, issue licenses, provide adequate enforcement, and create a transitional sales program for pharmaceutical processors. Any regulations produced under the bill would not take effect unless later approved by an act of the General Assembly, so the measure is a planning and reporting directive rather than an immediate legalization or implementation bill.
If enacted, SB1054 would amend Virginia’s cannabis regulatory framework by requiring the Cannabis Control Authority to prepare a detailed adult-use marijuana regulatory package and submit it to lawmakers for approval. It would not itself legalize retail cannabis sales or make new regulations effective, but it would create a formal legislative pathway for developing rules governing licensing, operations, enforcement, and transition planning. The bill would affect the Authority, prospective cannabis businesses, pharmaceutical processors, and adult consumers by setting the groundwork for a regulated market.
The available voting history suggests limited support in committee: the bill was passed by indefinitely in the Senate Committee on Rehabilitation and Social Services on a 15-0 vote, which indicates unanimous committee action to set it aside rather than advance it. With no recorded transcript discussion provided, the overall sentiment appears cautious or non-committal, reflecting interest in studying cannabis regulation but not moving forward with this proposal in its introduced form.
The main point of contention is the bill’s role in advancing adult-use cannabis regulation. Supporters would likely view it as a structured way to prepare regulations and a transition plan, while opponents or more cautious members may have objected to directing the Authority to draft rules for a market that would still require later legislative approval. The requirement to model regulations on the medical cannabis program, include transaction limits, and plan for pharmaceutical processor transitions may also have raised policy and implementation concerns, especially around enforcement capacity, licensing, and the timing of a retail market.